Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-fraction polysaccharide is a **protein-bound beta-glucan polysaccharide extract** from the maitake mushroom (*Grifola frondosa*), containing 1,3- and 1,6-beta-glucans as its main active components[5][2][3]. It exhibits **immunomodulatory, antitumor, and potential antidepressant activities**. D-fraction enhances immune functions by modulating natural killer (NK) cells, T-cells, and macrophages, and inhibits tumor growth in animal models and some human studies, with demonstrated activity in breast, prostate, lung, and liver cancers[5][2][1]. It may work as an adjunct in cancer therapy, helping mitigate side effects of chemotherapy and improving quality of life[5]. D-fraction also shows potential in management of chronic fatigue syndrome, HIV/AIDS, and metabolic conditions like diabetes and hypercholesterolemia[5][2]. Experimental evidence suggests a rapid-acting, long-lasting antidepressant effect in animals, with possible reduction of inflammatory pain symptoms[3]. D-fraction appears to be well tolerated, with no significant adverse effects reported[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on d-fraction polysaccharide.